AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AYTU • US0547548588

2.39 USD
+0.09 (+3.91%)
Last: Feb 6, 2026, 08:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AYTU. AYTU was compared to 191 industry peers in the Pharmaceuticals industry. AYTU may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AYTU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • AYTU had negative earnings in the past year.
  • AYTU had a negative operating cash flow in the past year.
  • AYTU had negative earnings in each of the past 5 years.
  • AYTU had a negative operating cash flow in each of the past 5 years.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of AYTU (-10.46%) is better than 65.44% of its industry peers.
  • AYTU has a Return On Equity (-56.41%) which is comparable to the rest of the industry.
  • The Return On Invested Capital of AYTU (1.26%) is better than 77.49% of its industry peers.
Industry RankSector Rank
ROA -10.46%
ROE -56.41%
ROIC 1.26%
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400 -500

1.3 Margins

  • Looking at the Operating Margin, with a value of 1.85%, AYTU is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
  • With a decent Gross Margin value of 67.56%, AYTU is doing good in the industry, outperforming 76.44% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
Industry RankSector Rank
OM 1.85%
PM (TTM) N/A
GM 67.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AYTU is destroying value.
  • The number of shares outstanding for AYTU has been increased compared to 1 year ago.
  • Compared to 5 years ago, AYTU has more shares outstanding
  • AYTU has a worse debt/assets ratio than last year.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • AYTU has an Altman-Z score of -2.89. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
  • AYTU has a Altman-Z score (-2.89) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.09 is on the high side and indicates that AYTU has dependencies on debt financing.
  • AYTU has a Debt to Equity ratio of 1.09. This is in the lower half of the industry: AYTU underperforms 73.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF N/A
Altman-Z -2.89
ROIC/WACC0.1
WACC12.33%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • AYTU has a Current Ratio of 1.23. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
  • AYTU's Current ratio of 1.23 is on the low side compared to the rest of the industry. AYTU is outperformed by 79.58% of its industry peers.
  • A Quick Ratio of 1.08 indicates that AYTU should not have too much problems paying its short term obligations.
  • AYTU has a Quick ratio of 1.08. This is in the lower half of the industry: AYTU underperforms 76.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.08
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for AYTU have decreased strongly by -206.03% in the last year.
  • The Revenue has been growing slightly by 1.84% in the past year.
  • AYTU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-206.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-303.85%
Revenue 1Y (TTM)1.84%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-6.48%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.77% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, AYTU will show a quite strong growth in Revenue. The Revenue will grow by 14.87% on average per year.
EPS Next Y54.04%
EPS Next 2Y37.45%
EPS Next 3Y29.77%
EPS Next 5YN/A
Revenue Next Year-20.09%
Revenue Next 2Y8.5%
Revenue Next 3Y9.37%
Revenue Next 5Y14.87%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AYTU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AYTU indicates a rather cheap valuation: AYTU is cheaper than 99.48% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.52
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AYTU's earnings are expected to grow with 29.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.45%
EPS Next 3Y29.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AYTU BIOPHARMA INC

NASDAQ:AYTU (2/6/2026, 8:18:49 PM)

2.39

+0.09 (+3.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)05-12
Inst Owners35.17%
Inst Owner Change1.37%
Ins Owners4.8%
Ins Owner Change1.1%
Market Cap24.35M
Revenue(TTM)66.38M
Net Income(TTM)-13.07M
Analysts82.22
Price Target9.52 (298.33%)
Short Float %5.63%
Short Ratio5.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3758.63%
Min EPS beat(2)-7706.78%
Max EPS beat(2)189.51%
EPS beat(4)3
Avg EPS beat(4)-1821.8%
Min EPS beat(4)-7706.78%
Max EPS beat(4)221.11%
EPS beat(8)6
Avg EPS beat(8)-879.29%
EPS beat(12)8
Avg EPS beat(12)-891.94%
EPS beat(16)10
Avg EPS beat(16)-685.51%
Revenue beat(2)1
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-17.2%
Max Revenue beat(2)9.83%
Revenue beat(4)3
Avg Revenue beat(4)6.63%
Min Revenue beat(4)-17.2%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)5.43%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)9
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)1.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)32.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB N/A
EV/EBITDA 0.52
EPS(TTM)-3.55
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS6.25
BVpS2.27
TBVpS-1.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.46%
ROE -56.41%
ROCE 2%
ROIC 1.26%
ROICexc 2.26%
ROICexgc N/A
OM 1.85%
PM (TTM) N/A
GM 67.56%
FCFM N/A
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF N/A
Debt/EBITDA 4.27
Cap/Depr 65.05%
Cap/Sales 4.85%
Interest Coverage 0.4
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.08
Altman-Z -2.89
F-Score3
WACC12.33%
ROIC/WACC0.1
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-206.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-303.85%
EPS Next Y54.04%
EPS Next 2Y37.45%
EPS Next 3Y29.77%
EPS Next 5YN/A
Revenue 1Y (TTM)1.84%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-6.48%
Revenue Next Year-20.09%
Revenue Next 2Y8.5%
Revenue Next 3Y9.37%
Revenue Next 5Y14.87%
EBIT growth 1Y177.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-189.88%
EBIT Next 3Y80.53%
EBIT Next 5YN/A
FCF growth 1Y-216.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.83%
OCF growth 3YN/A
OCF growth 5YN/A

AYTU BIOPHARMA INC / AYTU FAQ

Can you provide the ChartMill fundamental rating for AYTU BIOPHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to AYTU.


Can you provide the valuation status for AYTU BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to AYTU BIOPHARMA INC (AYTU). This can be considered as Overvalued.


How profitable is AYTU BIOPHARMA INC (AYTU) stock?

AYTU BIOPHARMA INC (AYTU) has a profitability rating of 3 / 10.


What is the earnings growth outlook for AYTU BIOPHARMA INC?

The Earnings per Share (EPS) of AYTU BIOPHARMA INC (AYTU) is expected to grow by 54.04% in the next year.